News · 9 June 2026

GSK acquires Nuvalent for $10.6bn, gains two lung cancer drugs.

Yenny.martinez.orjuela via Wikimedia Commons (CC0 1.0)

Patients with certain lung cancers could gain new treatment choices if medicines under review are approved later this year. GSK said on 9 June it would acquire US-based Nuvalent in a transaction worth $10.6bn, one of the largest purchases in its history. Led by chief executive Luke Miels, the agreement includes zidesamtinib and neladalkib, two late-stage non-small cell lung cancer treatments.

By BriefTea Editorial · 9 June 2026 at 8:52

Reported by The Guardian · How we write briefs

Get the app

More briefs

WorldKatie Zacharia leaves White House press secretary job after just five days WorldJamaica's slavery reparations case gets a London court date in March 2027 WorldSingapore threatens to prosecute firms behind Indonesia's worst fires in years as smoke spreads WorldFlash floods destroy villages in central Nepal TechnologyMeta releases Muse Spark Open, a new ‘open-weight’ AI model WorldIMF chief says AI needs safeguards before it runs people over Browse all stories →